Can a new drug tame metastatic prostate cancer? a phase 1 trial aims to find out

NCT ID NCT07735377

Not yet recruiting Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confirmed diagnosis of prostate adenocarcinoma with metastatic lesions and be in generally good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called SHR-6914
What this could lead to: If safe and effective, SHR-6914 could offer a new treatment option for metastatic prostate cancer.
What could go wrong: This is an early phase 1 trial with a small number of participants, focused on safety rather than proof of effectiveness. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.